FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (Sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With Egfr Mutations
FDA授予Sacituzumab Tirumotecan（Sac-TMT）用於治療某些已接受治療的晚期或轉移性非鱗狀非小細胞肺癌患者（伴有EGFR突變）突破性療法認定